Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin

Authors

  • Francis Vekeman,

    1. From the Groupe d'analyse, Ltée, Montréal, Québec, Canada; Centocor Ortho Biotech Services, LLC, Bridgewater, New Jersey; and Analysis Group, Inc., Boston, Massachusetts.
    Search for more papers by this author
  • Brahim K. Bookhart,

    1. From the Groupe d'analyse, Ltée, Montréal, Québec, Canada; Centocor Ortho Biotech Services, LLC, Bridgewater, New Jersey; and Analysis Group, Inc., Boston, Massachusetts.
    Search for more papers by this author
  • Joshua White,

    1. From the Groupe d'analyse, Ltée, Montréal, Québec, Canada; Centocor Ortho Biotech Services, LLC, Bridgewater, New Jersey; and Analysis Group, Inc., Boston, Massachusetts.
    Search for more papers by this author
  • R. Scott McKenzie,

    1. From the Groupe d'analyse, Ltée, Montréal, Québec, Canada; Centocor Ortho Biotech Services, LLC, Bridgewater, New Jersey; and Analysis Group, Inc., Boston, Massachusetts.
    Search for more papers by this author
  • Mei Sheng Duh,

    1. From the Groupe d'analyse, Ltée, Montréal, Québec, Canada; Centocor Ortho Biotech Services, LLC, Bridgewater, New Jersey; and Analysis Group, Inc., Boston, Massachusetts.
    Search for more papers by this author
  • Catherine Tak Piech,

    1. From the Groupe d'analyse, Ltée, Montréal, Québec, Canada; Centocor Ortho Biotech Services, LLC, Bridgewater, New Jersey; and Analysis Group, Inc., Boston, Massachusetts.
    Search for more papers by this author
  • Patrick Lefebvre

    1. From the Groupe d'analyse, Ltée, Montréal, Québec, Canada; Centocor Ortho Biotech Services, LLC, Bridgewater, New Jersey; and Analysis Group, Inc., Boston, Massachusetts.
    Search for more papers by this author

  • Financial disclosure: This research was supported by Centocor Ortho Biotech Services, LLC. FV, JW, MSD, and PL are employees of Groupe d'analyse, Ltée, and Analysis Group, Inc., which have received research grants from Centocor Ortho Biotech Services, LLC. BKB, RSM, and CTP are employees of Centocor Ortho Biotech Services, LLC.

  • Portions of this study were presented at the American Society of Hematology (ASH) 49th Annual Meeting and Exposition, December 8-11, 2007, Atlanta, GA; and the Society for the Advancement of Blood Management (SABM) Annual Meeting, September 12-14, 2008, Baltimore, MD.

Patrick Lefebvre, Vice President, Groupe d'analyse, Ltée, 1080 Beaver Hall Hill, Suite 1810, Montreal, QC, Canada H2Z 1S8; e-mail: plefebvre@analysisgroup.com.

Abstract

BACKGROUND: Recently, the Centers for Medicare and Medicaid Services issued a national coverage determination that limited erythropoiesis-stimulating agents (ESAs) utilization in patients with chemotherapy-induced anemia (CIA). This study evaluated the impact of limiting the use of ESAs for CIA on the US blood supply margin.

STUDY DESIGN AND METHODS: A modeling simulation was employed to compare the number of red blood cell (RBC) units transfused in CIA patients treated with ESAs to the number of RBC units that would be transfused if ESAs were limited or discontinued. The excess number of RBC units that would be required with limited ESA treatment was contrasted with the available marginal blood supply from 2004 and 2008. Model inputs were obtained from published literature or empirical evidence when published information was unavailable.

RESULTS: The model predicted that up to 18 and 15 percent of the respective 2004 and 2008 marginal US blood supply would be required to cover the incremental demand for blood that would arise from a 25 percent decrease in ESA use. For ESA use reductions of 50 and 75 percent, the model predicted 17 to 21 percent (134,667 units) and 26 to 31 percent (202,001 units) of the 2008 and 2004 marginal US blood supply would be required, respectively.

CONCLUSION: This study showed that limiting ESA use in CIA patients would impose considerable pressure on the available blood supply margin given the small margin between usable blood and transfusion demand. The public health consequences of such an outcome should be taken into account when revisions to ESA use are being considered.

Ancillary